MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Atypical Manifestations of Subacute Sclerosing Panencephalitis (SSPE): A Case Series from India

    G. Harikrishna, K. Mala, SK. Kodapala (MANDYA, India)

    Objective: To report unusual manifestations Subacute Sclerosing Panencephalitis. Background: Subacute Sclerosing Panencephalitis (SSPE) is a slow viral infection caused by measles virus resulting in progressive…
  • 2023 International Congress

    Efficacy and safety of deutetrabenazine in children and adolescents with dyskinesia in cerebral palsy

    D. Claassen, L. Dure, H. Barkay, S. Barash, G. Yiu, L. Voisin, L. Marinelli, P. Moshkov, J-M. Savola, M. Chen, N. Chaijale, M. Gordon, A. Ahn (Nashville, USA)

    Objective: To evaluate the efficacy and safety of deutetrabenazine (DTBZ) in children and adolescents with dyskinesia in cerebral palsy (DCP). Background: There are currently no…
  • 2023 International Congress

    AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

    L. Van_der Bent, C. Brouwers, A. Stam, L. Spronck, J. Klíma, J. Juhásová, B. Levinská, S. Juhás, J. Motlík, M. Evers, Z. Ellederova, A. Valles (Amsterdam, Netherlands)

    Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…
  • 2023 International Congress

    Recruiting for Parkinson’s disease risk: Successful engagement tactics to screen for hyposmia in undiagnosed individuals

    M. Kuhl, R. Dobkin, L. Lemon, C. Destro, C. Kelliher, T. Rosenbaum, N. Islam, K. Lynch, L. Heathers, M. Totten, E. Bryan, C. Stanley, C. Hobbick, B. Mcmahon, K. Fabrizio, K. Marek (New York, USA)

    Objective: Describe recruitment tactics for engaging community in Parkinson’s disease remote risk screening Background: Early clinical markers of PD are critical to identifying biomarker signatures…
  • 2023 International Congress

    Cortical thickness and global atrophy progression in Parkinson’s disease with probable RBD

    J. Oltra, A. Campabadal, C. Uribe, J. Pardo, I. Roura, MJ. Martí, Y. Compta, F. Valldeoriola, N. Bargallo, A. Iranzo, C. Junque, B. Segura (Barcelona, Spain)

    Objective: To explore 3-year cortical thickness (CTh) and global atrophy progression in treated Parkinson’s disease (PD) with probable REM sleep behavior disorder (RBD). Background: Parkinson’s…
  • 2023 International Congress

    The association between compliance and the effects of home-based touchscreen training in Parkinson’s disease

    J. de Vleeschhauwer, E. Nackaerts, Y. Zhang, L. Janssens, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium)

    Objective: To explore whether training success is determined by compliance as well as by cognitive function, depression and levodopa equivalent dosage (LEDD). Background: Training compliance…
  • 2023 International Congress

    Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain

    I. Muro Garcia, J. Alonso Maroto, B. Gonzalez Garcia, E. Carabajal Pendon, E. Casas, L. Lopez Manzanares (Madrid, Spain)

    Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…
  • 2023 International Congress

    Parkinson’s disease and Charcot-Marie-Tooth type 2: coincidental or causal?

    G. Prado-Miranda, S. Bansal, S. Sharma, M. Jog (London, Canada)

    Objective: To report a patient with Charcot-Marie-Tooth (CMT) type 2N (CMT2N) due to AARS gene mutation who developed early-onset Parkinson’s disease (PD). Background: Aminoacyl tRNA…
  • 2023 International Congress

    LRRK2 G2019S mutation in Multiple System Atrophy, a case report

    T. Carrer, G. Bonato, M. Sandre, A. Emmi, A. Antonini (Padova, Italy)

    Objective: Presenting a case of Multiple System Atrophy (MSA) confirmed by skin biopsy with a peculiar genetic profile. Background: MSA is a rare neurodegenerative disorder characterized…
  • 2023 International Congress

    Non-tremor motor dysfunction in Parkinson’s disease is associated with decreased [18F]FMPEP-d2 binding

    R. Ajalin, H. Al-Abdulrasul, J. Tuisku, J. Hirvonen, S. Lahdenpohja, J. Rinne, A. Brück (Espoo, Finland)

    Objective: To explore the relationship between cannabinoid receptor type 1 (CB1) availability and motor symptoms in Parkinson’s disease (PD) with [18F]FMPEP-d2 positron emission tomography (PET).…
  • « Previous Page
  • 1
  • …
  • 256
  • 257
  • 258
  • 259
  • 260
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley